: Overall Financial Performance Unit: million baht Jan-Jun 2018 % Jan-Jun 2019 % Change % YoY Revenue 254.34 100.0% 273.96 100.0% 19.62 7.7% Cost 144.42 56.8% 147.42 53.8% 3.00 2.1% Gross Profit 109.92 43.2
Revenues and Net Profit Consolidated FS Q1/2019 Q1/2020 Change MB. % MB. % MB. % Revenue from contracts with customers 89.9 16.3% 97.1 12.7% 7.1 7.9% Interest income and dividend income 336.4 60.9% 362.8
financial statements for the three-month period ended 31 March 2019 and 2020 Revenues Q1/20 Q1/19 Change +/(-) Revenue from hotel operations 232 367 (36.9) Revenue from property development operations 238 115
million or 4.51 percent. Such change was mainly because of the decrease in short-term loans from related companies, the increase in short-term loans from financial institutions, and the recognition of
Change DOD BIOTECH PUBLIC COMPANY LIMITED เลขท ี111 หมู่ท ี2 ตําบลท่าจีน อําเภอเมืองสมุทรสาคร จังหวดัสมุทรสาคร 74000 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 As of March 31, 2020
%, compared with the same period of the last year. As a result of operating profit that significant growth and finance costs are very low level because of the stable financial position. DOD BIOTECH PUBLIC
maintaining net liquid capital as of the date on which the securities business license becomes effective at the level not less than the rate specified by the SEC; (4) in cases where the finance and securities
class. Set scope 3 decarbonization targets if the emissions are material (at an asset and/or sector level) and where data is available. Set portfolio targets aligned with the global goal of tackling
Code 2017 Concept CG Code Practice Notes SET Ministry of Commerce Other related entities Company Profile Assessment National level Listed company level Archive CG CSR Anti-corruption AGM FAQ News
Notes SET Ministry of Commerce Other related entities Company Profile Assessment National level Listed company level Archive CG CSR Anti-corruption AGM FAQ News/Events FAQ Board roles and responsibilities